Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
MYO3A encodes myosin IIIA (1,616 aa). Actin-dependent motor protein with a protein kinase activity, playing an essential role in hearing. Probably also plays a role in vision. Highest expression in Testis (6.3 TPM) and Artery Tibial (2.0 TPM).
Hearing loss, autosomal dominant 90 is associated with mutations in the MYO3A gene on chromosome 10.
MYO3A is classified as a druggable target (Druggable Genome, Enzyme, Kinase, and Serine Threonine Kinase categories) with score 0.0.
Genetic testing for MYO3A is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hearing loss, autosomal dominant 90 has been reported in the published literature.
No clinical trials have been registered for hearing loss, autosomal dominant 90.
10 publications have been identified in PubMed for hearing loss, autosomal dominant 90. Research spans Case Report / Case Series (30%), Epidemiology / Natural History (30%), and Diagnostic / Biomarker (20%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 3 | 30% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:55 PM UTC
Online Mendelian Inheritance in Man
Disease patterns and progression
3 |
30% |
Testing and diagnosis research | 2 | 20% |
Research summaries | 2 | 20% |
Sampath Kumar D (2026). [PMID: 41782702](https://pubmed.ncbi.nlm.nih.gov/41782702/). *Clin Nephrol Case Stud*. [Case Report / Case Series]
Yadav M (2025). [PMID: 39278986](https://pubmed.ncbi.nlm.nih.gov/39278986/). *Pediatr Nephrol*. [Epidemiology / Natural History]
Damrongchietanon T (2025). [PMID: 40998904](https://pubmed.ncbi.nlm.nih.gov/40998904/). *Sci Rep*. [Diagnostic / Biomarker]
Elbagoury NM (2025). [PMID: 40100472](https://pubmed.ncbi.nlm.nih.gov/40100472/). *Eur J Pediatr*. [Diagnostic / Biomarker]
Nayak Manel D (2025). [PMID: 40016832](https://pubmed.ncbi.nlm.nih.gov/40016832/). *J Med Case Rep*. [Review / Meta-Analysis]
Maekawa K (2025). [PMID: 39858639](https://pubmed.ncbi.nlm.nih.gov/39858639/). *Genes (Basel)*. [Epidemiology / Natural History]
He M (2024). [PMID: 39020321](https://pubmed.ncbi.nlm.nih.gov/39020321/). *BMC Med Genomics*. [Case Report / Case Series]
Giuca MR (2024). [PMID: 39212455](https://pubmed.ncbi.nlm.nih.gov/39212455/). *Eur J Paediatr Dent*. [Review / Meta-Analysis]
Driesen J (2024). [PMID: 38790272](https://pubmed.ncbi.nlm.nih.gov/38790272/). *Genes (Basel)*. [Case Report / Case Series]
Wu B (2024). [PMID: 37656934](https://pubmed.ncbi.nlm.nih.gov/37656934/). *Rheumatology (Oxford)*. [Epidemiology / Natural History]